JGC
XENE icon

J. Goldman & Co’s Xenon Pharmaceuticals XENE Stock Holding History

J. Goldman & Co’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,500
Closed -$526K – 640
2024
Q2 		$526K Buy
+13,500
New +$540K 0.01% 357
2024
Q1 		– Sell
-67,500
Closed -$3.11M – 539
2023
Q4 		$3.11M Buy
+67,500
New +$2.38M 0.13% 158

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

J. Goldman & Co's XENE Position: Q4 2023 in Review

J. Goldman & Co sold out of Xenon Pharmaceuticals (XENE) in Q4 2023, closing a stake of 17,775 shares — an estimated $628K sold.

J. Goldman & Co first reported a position in XENE in Q1 2017 and held it in 5 quarters. The position peaked at $1.85M in Q2 2023. 204 funds tracked by Wall St. Rank hold XENE as of Q4 2023.

  • J. Goldman & Co reported no remaining Xenon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • J. Goldman & Co sold 17,775 Xenon Pharmaceuticals shares in Q4 2023, an estimated $628K.
  • J. Goldman & Co first reported a position in Xenon Pharmaceuticals in Q1 2017 and held it in 5 quarters.
  • J. Goldman & Co's Xenon Pharmaceuticals position peaked at $1.85M in Q2 2023.
  • 204 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.